Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 2, 2018, at the Annual Meeting, the Company’s stockholders voted on the following three (3) proposals and cast their votes as described below. These matters are described in detail in the Definitive Proxy Statement.
Proposal 1 — Election of Directors
The following four (4) individuals were elected as directors, to serve until the 2019 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified with the following votes:
|
Name of Director |
VotesFor |
Withheld |
BrokerNon-Votes |
|
1. Jeffrey Wolf |
2,122,376 |
98,844 |
6,772,754 |
|
2. John Monahan, Ph.D. |
2,140,870 |
80,350 |
6,772,754 |
|
3. Edward B. Smith, III |
2,089,612 |
131,608 |
6,772,754 |
|
4. John Prendergast, Ph.D. |
2,140,976 |
80,244 |
6,772,754 |
Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm
The stockholders ratified and approved the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018 based on the votes listed below:
|
VotesFor |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|
8,758,085 |
28,379 |
207,510 |
|
Proposal 3 — Approval of our 2018 Stock Incentive Plan
As further described above in Item 5.02 of this Current Report on Form 8-K, the stockholders approved and adopted the Company’s 2018 Stock Incentive Plan, which would allow the Company to grant up to 4,000,000 awards under the 2018 Stock Incentive Plan, based on the votes listed below:
|
VotesFor |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|
1,990,722 |
99,411 |
131,087 |
6,772,754 |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
